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Abstract
Background: Cellular reprogramming is a stressful process, which requires cells to engulf somatic features and
produce and maintain stemness machineries. Autophagy is a process to degrade unwanted proteins and is
required for the derivation of induced pluripotent stem cells (iPSCs). However, the role of autophagy during
iPSC maintenance remains undefined.
Methods: Human iPSCs were investigated by microscopy, immunofluorescence, and immunoblotting to detect
autophagy machinery. Cells were treated with rapamycin to activate autophagy and with bafilomycin to block
autophagy during iPSC maintenance. High concentrations of rapamycin treatment unexpectedly resulted in
spontaneous formation of round floating spheres of uniform size, which were analyzed for differentiation into three
germ layers. Mass spectrometry was deployed to reveal altered protein expression and pathways associated with
rapamycin treatment.
Results: We demonstrate that human iPSCs express high basal levels of autophagy, including key components of
APMKα, ULK1/2, BECLIN-1, ATG13, ATG101, ATG12, ATG3, ATG5, and LC3B. Block of autophagy by bafilomycin
induces iPSC death and rapamycin attenuates the bafilomycin effect. Rapamycin treatment upregulates autophagy
in iPSCs in a dose/time-dependent manner. High concentration of rapamycin reduces NANOG expression and
induces spontaneous formation of round and uniformly sized embryoid bodies (EBs) with accelerated differentiation
into three germ layers. Mass spectrometry analysis identifies actin cytoskeleton and adherens junctions as the major
targets of rapamycin in mediating iPSC detachment and differentiation.
Conclusions: High levels of basal autophagy activity are present during iPSC derivation and maintenance.
Rapamycin alters expression of actin cytoskeleton and adherens junctions, induces uniform EB formation, and
accelerates differentiation. IPSCs are sensitive to enzyme dissociation and require a lengthy differentiation time. The
shape and size of EBs also play a role in the heterogeneity of end cell products. This research therefore highlights
the potential of rapamycin in producing uniform EBs and in shortening iPSC differentiation duration.
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Background
Induced pluripotent stem cell (iPSC) technology enables
conversion of patients’ somatic cells into embryonic
stem (ES)-like cells [1] which can be differentiated into
the major cell types in the body, raising the expectation
of personalized medicine to treat patients with their own
somatic tissue-derived cells. This technology also offers an
opportunity to generate human cell models of diseases for
therapeutic development, which has not kept pace with
pharmaceutical investment in recent decades. A major
impediment to drug discovery is attributable to the lack of
suitable disease models of human origin, because species
differences may totally affect drug efficacy [2]. Some
disease pathologies are shown to be recapitulated in the
culture dish. For example, many patient-specific iPSCs
have been generated to investigate disease progression in
vitro and disease-related phenotypes are partially
preserved in iPSC-derived cells [3–6]. Recent successes in
the growth of “mini-organs”—that is, 3D retina [7, 8] and
cerebral organoids [9]—may provide 3D human disease
models. However, there are challenges in phenotyping
iPSCs prior to the development of screening assays, which
include lengthy differentiation durations and heterogeneity
of the end cell products.
The differentiation, survival, and self-renewal of human
stem cells can be regulated by a 3D microenvironment
including shape and size [7–10]. Human iPSCs are hyper-
sensitive to cell dissociation reagents, and seconds of
exposure to Trypsin/EDTA may lead to failure of iPSC ad-
hesion or survival. Consequently, many laboratories adopt
a “cut-and-paste” method to mechanically passage iPSCs,
which results in embryoid bodies (EBs) of uncontrollable
sizes with irregular shapes, which may potentially contrib-
ute to the heterogeneity. The differentiation of mature cell
types from human iPSCs is also time consuming. For
example, 3–5 months are required to generate functional
neurons, astrocytes, or oligodendrocytes [11–13]. There-
fore, accelerated differentiation remains to be optimized.
Efforts have been made to improve the reprogramming
efficiency, and autophagy, a process to degrade unwanted
proteins, is found to be one of the regulators during cellu-
lar reprogramming [14, 15]. Autophagy is conserved from
yeast to mammals, and is generally induced by intracellular
and extracellular stress. Upon induction, the preautopha-
gosomal structure is formed and elongated to form a pha-
gophore, which engulfs cytoplasmic components, leading
to the formation of autophagosomes with double mem-
branes. The genes involved in the autophagy are termed
autophagy-related genes (ATGs), and >12 ATGs have been
identified. They regulate autophagosome formation
through two evolutionarily conserved ubiquitin-like conju-
gation systems, the ATG12–ATG5 and the ATG8 (LC3)–
PE (phosphatidylethanolamine) systems [16]. Microtubule-
associated proteins 1A/1B light chain 3-I (LC3B-I) is
conjugated with PE to become LC3B-II, which associates
with both the outer and inner membranes of the autopha-
gosome. After fusion with the lysosome, the autolysosome
is degraded [17]. In mice, Atg3, Atg5, and Atg7 are essen-
tial for reprogramming of mouse embryonic fibroblasts
[14, 15]. Cells lacking Atg3, Atg5, or Atg7 abrogate iPSC
colony formation [15].
The autophagy pathway can be activated by AMPK
signaling, but is normally inhibited by the mammalian
target of rapamycin (mTOR) pathway. The presence of
hyperactivated mTOR activity in Tsc2–/– somatic cells
completely blocked reprogramming [14]. Consistent
with this, rapamycin (an inhibitor of the mTOR pathway
at 0.3–1 nM) could increase reprogramming efficiency by
2–3-fold [18]. In addition, 0.1 nM of PP242, a selective
inhibitor of mTORC1/mTORC2 binding at the ATP do-
main, also increased reprogramming efficiency by 5-fold
[18]. Other compounds associated with autophagy such as
PQ401 (an IGF1 receptor inhibitor) and LY294002 (an in-
hibitor of PI3K) also increased reprogramming by 4-fold
[18]. Mechanistically, mTOR is regulated by SOX2, one of
the four reprogramming factors. SOX2 can physically bind
to the mTOR promoter and repress mTOR expression,
thereby activating autophagy [15]. An appropriate level of
autophagy is therefore required for cell reprogramming.
However, roles of autophagy in iPSC maintenance and
differentiation remain elusive.
In this study, we showed the presence of high levels of
basal autophagy activity during iPSC reprogramming
and maintenance. Rapamycin alters expression of
adherens junctions and actin cytoskeleton, induces iPSC
detachment, and results in uniform EB formation.
Rapamycin treatment also accelerates differentiation of
human iPSCs into three germ layers.
Methods
iPSC derivation
On day 0, human fibroblasts were seeded at a density of
2.0 × 104 cells/well on a six-well dish. Next day, cells
were transduced with a polycistronic (OKSM) lentivirus
containing four reprogramming factors (SCR544-Human
STEMCCA constitutive lentivirus reprogramming kit,
SCR544; Millipore) in 700 μl of fibroblast medium,
supplemented with 4 μg/ml polybrene (TR-1003;
Millipore). On day 2, cells were repeatedly transduced
with lentivirus. The medium was then replaced daily
with complete fibroblast medium supplemented with
0.25 mM sodium butyrate (NaB, 156-54-7; Sigma) for
4 days. On day 6, six-well dishes were preseeded with
γ-irradiated MEF (07GSC6001G, VH Bio Limited) at a
density of 1.5 × 105 cells/well. On day 7, transduced
cells were trypsinized with 0.25 % Trypsin/EDTA,
replated onto preseeded MEF dishes at a density of
3.0 × 104 cells/well, and cultured in KO iPSC medium
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supplemented with 10 ng/ml bFGF (100-18B; Peprotech)
plus 0.25 mM NaB. The medium was changed every other
day. The addition of NaB was discontinued after day 20.
Individual iPSC colonies began to emerge after day 14
and were picked up on day 28, mechanically dissociated
into smaller pieces by pipetting, and plated into γ-MEF-
coated 12-well plates. Selected clones were characterized
using alkaline phosphatase activity, RT-PCR, and im-
munoblotting to detect endogenous expression of OCT4,
SOX2, and NANOG, and immunocytochemistry to detect
surface markers of SSEA4, TRA 1-60, and TRA 1-81 in
addition to the transcription factors (StemLight™ pluripo-
tency antibody kit, 9656; Cell Signaling Technology).
Cell culture
Human iPSC lines were maintained on a feeder-free
culture system. The six-well plates were precoated with
Geltrex, LDEV-free hESC-qualified reduced growth factor
basement membrane matrix (A1413302; Invitrogen).
Geltrex was thawed overnight at 4 °C and diluted 1:100 in
KO-DMEM medium (10829018; Invitrogen). Each well
was coated with 1.5 ml Geltrex and incubated for 1 hour
at 37 °C, which was then replaced with the mTeSR1
medium (05850; StemCell Technologies) with 10 ng/ml
bFGF at 37 °C and 5 % CO2. iPSCs were cut and pasted
into Geltrex-coated wells. The medium was renewed daily
and passaged every 6 days. Chemicals such as rapamycin
were then added to respective experiments.
For induction of autophagy signaling, iPSC colonies
were cultured in mTeSR1 medium supplemented with
0–300 nM rapamycin (R8781; Sigma) for 1–9 days. For
autophagic flux assay, human iPSCs were treated with
200 nM rapamycin in the absence or presence of 50 nM
bafilomycin A1 for 24 hours (B1793; Sigma) as specified.
Cells were collected and protein was subsequently ana-
lyzed by immunoblotting.
EB formation by cut-and-paste method
The cut-and-paste method was deployed to make con-
ventional EBs as iPSCs. Spontaneously differentiated
cells were removed under a stereomicroscope inside the
culture safety cabinet, and fresh medium was added to
the remaining iPSC colonies, which were cut into small
pieces with a 10 μl pipette tip. The iPSC sections were
then scraped off the dish and transferred to a T25 flask
in 15 ml EB medium (KO DMEM, KO serum, 1× L-glut,
and 1× NNEA plus 50 μl β-mercaptoethanol). The
medium was changed every other day, and the EBs were
cultured for 7–10 days before plating out for spontan-
eous differentiation assays.
Antibodies and reagents
The reagents for transmission electron microscopy
(TEM) include sodium cacodylate (C0250; Sigma), low
viscosity resin kit (AGR1078A; Agar Scientific), 2 % os-
mium tetroxide (AGR1016; Agar Scientific), 25 % glutaral-
dehyde solution (23114.02; AMSBIO), and thermanox
plastic coverslips (NUNC). For immunocytochemistry, the
following antibodies were used: anti-LAMP1 (25630),
anti-Syntaxin-6 (12370), and anti-NESTIN (105389) from
Abcam; SelectFX® Alexa Fluor® 488 Endoplasmic
Reticulum labeling kit (S34200) from Life Technologies;
and anti-LC3B from autophagy antibody sampler kit
(4445), Alexa Fluor® 488 Goat Anti-Rabbit IgG fluorescent
dye (4412), and Alexa Fluor® 555 Goat Anti-Mouse IgG
fluorescent dye (4409) from Cell Signaling Technology.
For immunoblot experiments, reagents included: anti-α-
fetoprotein (A8452), anti-α-smooth muscle actin (A2547),
anti-ATG13 (SAB3500502), and ATG101 (SAB3500503)
from Sigma; anti-βIII tubulin (G7121) from Promega Cor-
poration; anti-ULK2 (56736) from Abcam; and anti-LC3B,
anti-BECLIN-1, anti-ATG5 (D1G9; #8540P, 1:1000), anti-
ATG12 and anti-ATG3 autophagy antibody sampler kit
(4445), anti-p-ULK1 (Ser317, 6887), anti p-p70S6K
(Thr389, 9205), anti-β-Actin (4967), HRP-conjugated
anti-mouse IgG antibody (7076), and HRP-conjugated
anti-rabbit-IgG antibody (7074) from Cell Signaling
Technology. MitoGreen (a green-fluorescent mitochon-
drial dye) was purchased from Promokine (PK-CA707-
70054).
Transmission electron microscopy
iPSCs were cultured on Thermanox coverslips in six-
well plates coated with Geltrex, rinsed with prewarmed
(37 °C) 0.1 M cacodylate buffer, fixed with 2 % glutaral-
dehyde and 2 % paraformaldehyde in 0.1 M cacodylate
buffer for 3 hours at room temperature, rinsed again
with cacodylate buffer, and post fixed with 1 % osmium
tetroxide in cacodylate for 1 hour at room temperature.
Samples were then rinsed with cacodylate buffer, dehy-
drated through a series of graded ethanol, embedded in
low-viscosity resin according to the standard protocol,
and polymerized at 60 °C for 48 hours. Ultra-thin
sections were obtained using a diamond knife, on a Leica
Reichert Jung ultra-microtome, and stained with the
contrasting agents, uranyl acetate and lead citrate, in a
Leica EM AC20 stainer. Sections were examined with a
Hitachi H7000 transmission electron microscope fitted
with a 1 K Hamamatsu digital camera, and images were
captured using AMTV542 Image Capture Engine
software.
Immunocytochemistry
To investigate the effect of rapamycin, iPSC colonies or
the EB-like spheres were transferred to a μ-Slide eight-
well glass bottom flask (80826; ibidi GmBH) coated with
Geltrex. Cells were fixed with 4 % paraformaldehyde for
10 min at room temperature and washed with PBS three
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times before permeabilization using 0.5 % Triton X-100
for 10 min. Nonspecific binding was blocked with 5 %
normal goat serum in PBS containing 0.5 % Trion X for
1 hour prior to incubation with primary antibodies
overnight at 4 °C. The wells were washed three times
with PBS and incubated with secondary antibodies for
1 hour at room temperature. The nuclei were visualized
by Hoechst counterstaining for 10 min. After washing
with PBS, the immunofluorescence was visualized with
the Andor Revolution spinning disk confocal microscope,
using Andor IQ2 software. The samples were imaged
using a combination of λ405 nm, λ488 nm and λ564 nm
lasers.
Immunoblotting
Following experimental treatments, cell pellets were re-
suspended in NP40 cell lysis buffer (FNN0021; Invitrogen)
supplemented with protease inhibitor cocktail (P2714;
Sigma). Lysate was then centrifuged at 13,000 rpm for
10 min at 4 °C, and the supernatant was collected and
used for immunoblotting. The protein concentration was
determined and the samples were denatured in sample
buffer (62.5 mM Tris–HCl pH 6.8, 2 % SDS, 10 % glycerol,
2 % mercaptoethanol, and 0.01 % bromophenol blue) at
95 °C for 5 min. Proteins were resolved on 10–15 % SDS-
PAGE gels and then electrophoretically transferred to a
polyvinylidene difluoride (PVDF) membrane (162-0177;
Bio-Rad). The transfer efficiency was checked by
Ponceau-S red staining (P7170; Sigma). The membranes
were washed with Tris-buffered saline containing 0.1 %
Tween-20 (TBST) for 5 min, incubated in blocking buffer
for 1 hour at room temperature, and incubated overnight
at 4 °C with primary antibodies. They were then washed
three times for 5 min each with TBST, incubated with
secondary antibodies for 1 hour at room temperature, and
washed in TBST. Finally, the membranes were visualized
by enhanced chemiluminescence using ECL™ Prime
(GZ28980926; Amersham Biosciences). The immunoblot
band densities were normalized with the unphosphorylated
protein, actin, or GAPDH, and quantified using a
densitometer in the Scion image analysis program
(National Institutes of Health, Bethesda, MD, USA).
Data analysis and statistical methods
Data were expressed as the mean ± standard error of
means (SEM) or mean ± SD as indicated. Significance was
assessed using one-way analysis of variance (ANOVA)
followed by the Tukey–Kramer test using GraphPad Prism
version 5. p < 0.05 was considered significant, and p < 0.01
very significant.
Mass spectrometry analysis
The iPSCs were lysed in 1 % SDS and the lysates were
processed using the FASP protocol as published previously
[19]. Briefly, the cell lysates were sonicated, detergents
were removed by sequential washes in spin columns, and
proteins were digested with trypsin. The peptides were an-
alyzed on a Q-Exactive Mass Spectrometer as described
previously [20]. The proteins were identified and quantified
with the MaxQuant 1.5 software suite by searching against
the human uniprot database, with N-terminal actylation
and methionine oxidation as variable modification and a
FDR of 0.01. Mass accuracy was set a 4.5 ppm for the MS
and 20 ppm for the MS/MS. LFQ was performed by
MaxLFQ as described previously [21]. One-way ANOVA
was carried out to compare rapamycin-treated samples
with control iPSCs. The mean expression levels (M) and
SEM were quantified, and folds of changes in the treated
samples were calculated against the control iPSCs (set
as 1). p < 0.05 was considered statistically significant.
A total of 220 proteins which were significantly
altered after rapamycin treatment were analyzed by
the STRING program for pathway using GO bio-
logical processes and GO cellular components.
Results
Autophagy is a prominent feature of reprogramming cells
and stable iPSCs
The autophagy–lysosome and ubiquitin–proteasome
systems are the two major pathways that cells employ to
selectively target long-lived and misfolded proteins,
protein aggregates, damaged mitochondria, or unwanted
cytoplasmic components and organelles [22]. We ob-
served large autophagic vacuoles in the majority of cells
during early reprogramming (Fig. 1a). In young passages
of stable iPSCs, autophagic vacuoles were abundantly
present but reduced in size (Fig. 1b). However, large
autophagic vacuoles were absent in parental fibroblasts
(Fig. 1f). TEM revealed the presence of lysosomal struc-
tures (Fig. 1e, i) in iPSCs. Structures of endosomal/lyso-
somal nature with double membranes were clearly evident
under high magnification, which were filled with an array
of cell debris and organelles (Fig. 1j–l).
Double immunofluorescence staining was carried out
with anti-LC3B (an autophagy marker) and anti-LAMP1
(a major component of lysosomal membrane). In fibro-
blasts, fine dots of LC3B staining (Fig. 1g) were observed
and most of them were not colocalized with LAMP1
(Fig. 1g). Similar to fibroblasts, small dots of LC3B
staining were observed in iPSC culture which were not
colocalized with LAMP1. However, strong LC3B staining
appeared in large vacuoles (Fig. 1c) which colocalized
with anti-LAMP1 staining, which could represent differ-
ent status of LC3B activity. The control double staining
was performed with anti-Syntaxin 6, a marker for Golgi
membrane, and MitoGreen for mitochondria (Fig. 1d, h).
As anticipated, there was no colocalization in either iPSCs
(Fig. 1d) or fibroblasts (Fig. 1h). These data therefore
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demonstrate that large autophagic vacuoles are a charac-
teristic feature of iPSCs which harbor both LC3B-II and
LAMP1.
iPSCs exhibit higher abundance of LC3B-II than parental
fibroblasts
Next we compared iPSCs with parental fibroblasts from
four independent donors by both immunocytochemistry
(Fig. 2a–D′) and immunoblotting (Fig. 2E–G). The im-
munofluorescence study showed brighter basal LC3B-II
staining in iPSCs (Fig. 2A–D) than in parental fibroblasts
(Fig. 2a–d). Rapamycin (100 nM) induced autophagy in
both iPSCs (Fig. 2A′–D′) and fibroblasts (Fig. 2a′–d′).
Quantification of the immunoblots (Fig. 2E) showed 2.55-
fold higher basal LC3B-II in the iPSCs than that in paren-
tal fibroblasts (Fig. 2F, p < 0.01, n = 4). After 1 day of
rapamycin induction at 100 nM, LC3B-II was also 2.23-
fold higher in the iPSCs than in fibroblasts (Fig. 2g,
p < 0.05, n = 4). Overall, these data show that autophagy is
highly active in human iPSCs and is rapamycin-inducible.
Both the basal and induced autophagy is significantly
higher in iPSCs than in dermal fibroblasts.
High basal levels of autophagy components are
expressed in iPSCs
To further address the autophagy activity during iPSC
maintenance, we determined basal expression levels of
10 autophagy members involving different steps of
autophagy. Autophagy is repressed by the mTOR and
activated by rapamycin. ULK1/2 are activated in a
ULK1/2–Atg13/101–FIP200 complex [23, 24], which
subsequently activates PI3K CIII complex (consisting
Fig. 1 Autophagy machinery is widely operated in iPSCs. (a) Images of cells taken at day 15 of fibroblast reprogramming and large autophagic
vacuoles indicated (red arrowheads). (b) Smaller autophagic vacuoles (red arrowheads) were observed in stable iPSC lines with daily change of
culture medium. (c, d, g, h) Double immunofluorescence staining of iPSCs (c, d) and fibroblasts (g, h) was carried out with anti-LC3B for autophagy
(c, g green) and anti-LAMP1 for lysosome (c, g red), Syntaxin 6 for Golgi membrane (d, h red) and MitoGreen (d, h green) for mitochondria, with
counter-staining of DAPI (blue) for nuclei. Fluorescent images were acquired via confocal microscopy. Note that LC3B and LAMP1 are colocalized in
iPSCs (c) but not in fibroblasts (g), whereas Syntaxin 6/MitoGreen are not colocalized as anticipated (d, h). (e, i–l) TEM images showed a dead nucleus
(* a, e), lysosomal structures (blue arrowheads, e, i), and autophagic vacuoles (red arrowheads, j–l). Bar= 20 μm a–d and f–h; 10 μm e, i; 500 nm j–l
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of BECLIN-1, AMBRA, VPS34/15, and ATG14) and
stimulates phagophore formation. ATG12 then conju-
gates with ATG5/16 and forms phagophores [25].
ATG4/7/3 then converts LC3B-I to LC3B-II to form
autophagic vacuoles [17, 22, 26, 27]. We extracted
proteins from 12 iPSC lines derived from 10 inde-
pendent donors (Fig. 3), and carried out immunoblot-
ting with antibodies against AMPKα, ULK1, ULK2,
ATG13, ATG101, BECLIN-1, ATG3, ATG5, ATG12,
and LC3B. Relative protein abundance was quantified
against housekeeping proteins. AMPKα, BECLIN-1
ATG12, ATG13, and ULK1 were shown to be highly
expressed in iPSCs, whereas ATG3, ATG101, and
ULK2 were less abundant. No significant difference
was detected among different lines for each compo-
nent, but high levels of LC3B-II were detected in all
iPSCs line (Fig. 3a, c). To further evaluate the differ-
ence between iPSCs and fibroblasts, we investigated
ATG5 and ATG12 expression among three fibroblast
lines and five iPSC lines. The iPSCs were consistently
shown to have much higher ATG5/ATG12 expression
compared with fibroblasts (Fig. 3h). These data
Fig. 2 iPSCs exhibit higher autophagy activity than parental fibroblasts. Fibroblasts (a–d, a′–d′) and iPSCs (A–D, A′–D′) derived from four independent
donors were cultured in the absence (–R) or presence (+R) of 100 nM rapamycin for 24 hours. iPSCs showed higher basal staining of LC3B (A–D) than
in parental fibroblasts (a–d). LC3B was highly induced by 100 nM of rapamycin in iPSCs (A′–D′), with lower levels of induction in their respective
fibroblasts (a′–d′). Fluorescent images were acquired via confocal microscopy. Bar = 10 μm. (E) Immunoblots of the protein extracts from
untreated (–R) or treated (+R) cells with anti-LC3B-II and anti-β-ACTIN. (F, G) The relative abundance of LC3B-II was quantified using
ImageJ software and data were presented as mean ± SD. (F) The basal level of LC3B-II in the iPSCs was 2.55-fold higher than in parental
fibroblasts (**p < 0.01, n = 4). (G) Rapamycin-induced expression of LC3B-II in the iPSCs was also 2.23-fold higher than fibroblasts (*p < 0.05, n = 4).
Fib fibroblasts, iPSC induced pluripotent stem cell
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demonstrate that most autophagy components are
abundantly expressed in iPSCs.
Rapamycin induces iPSC autophagy in concentration-
dependent and time-dependent manners
To determine whether iPSC maintenance might
benefit from upregulated autophagy, we investigated
the dosage effect of rapamycin on phosphorylated
ULK1, p70S6K, and the autophagy indicator—ratio
of LC3B-II/I. Both ULK1 and p70S6K are serine/
threonine kinases and targets of mTOR. p70S6K is a
major regulator of translation and phosphorylated by
mTOR [28–30], whereas ULK1 is an initiator of
autophagy.
Fig. 3 Wide expression of different autophagy components in independent iPSC lines. Proteins were extracted from iPSCs with daily renewal of
culture medium. Then 15 μg of protein was loaded onto each lane. Lanes a–l represent 12 independent iPSC lines from 10 donors (1, 33D6; 2,
JOM; 3, LV1; 4, LV2; 5, LV3; 6, 001CC1; 7, NRXN1C1; 8, 002 V; 9, 003 V; 10, SC126; 11, SC128; 12, SC132). (a–c) Immunoblotting was carried out with
antibodies against LC3B-I, LC3B-II, BECLIN-1, AMPKα, ULK1, ULK2, ATG3, ATG12, ATG13, ATG101, and β-actin. (d–g) The relative abundance of the
proteins was quantified using ImageJ software against β-actin and data were presented as mean ± SD. (h) Immunoblots were carried out to compare
expression of ATG5 and ATG12 among three fibroblast lines (3× Fib.) and five iPSC lines (5× iPSCs) of healthy donors, showing higher ATG5 and ATG12
expression in iPSCs than that in fibroblasts. iPSC induced pluripotent stem cell
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We treated iPSCs with 0, 1, 10, 100, 200, or 300 nM of
rapamycin for 4 days, and observed a dose-dependent
reduction in p70S6K phosphorylation (Fig. 4i). The most
significant reduction was achieved with 100–300 nM
(Fig. 4k). In contrast, LC3B-II (Fig. 4j) and p-ULK1
(Fig. 4l) were enhanced in a dose-dependent manner,
and the maximal increase was observed at 200 nM of
rapamycin (p < 0.01). Similarly, immunostaining detected
higher levels of LC3B-II expression in 200 nM
rapamycin-induced cells (Fig. 4a–d).
We then treated iPSCs with 200 nM of rapamycin for
1, 3, and 6 days, observed significantly clustered LC3B-II
staining after 3 days of rapamycin treatment, and
showed a time-course-dependent activation of autoph-
agy (Fig. 4e–h). This result was different from that for
fibroblasts, in which the total LC3B was increased by
24 hours of rapamycin treatment whereas the LC3B-II
remained relatively constant (Additional file 1: Figure S1).
These data demonstrate that autophagy can be markedly
activated by rapamycin in iPSCs.
Rapamycin attenuates bafilomycin-induced iPSC death
Bafilomycin A1 is an inhibitor of lysosome degradation
by blocking the final stage of autophagy, fusion of
Fig. 4 Rapamycin induces autophagy in time-dependent and concentration-dependent manners in iPSCs. iPSCs were maintained in six-well plates
and medium was renewed daily. Images of LC3B staining were taken at 4 days of rapamycin treatment at 0, 10, 100, or 200 nM respectively (a–d)
and for 200 nM of rapamycin treatment at 1, 3, and 6 days respectively (e–h), showing concentration-dependent and time-dependent induction.
(i) Proteins were extracted from iPSCs treated with rapamycin at 0, 1, 10, 100, 200, or 300 nM for 4 days, and immunoblotted with antibodies against
LC3B, phosphorylated ULK1, phosphorylated p70S6K, or β-actin. (j–l) Relative abundance of the LC3B-II/I ratios (j), p-p70S6K (k), and p-ULK1 (l) was
quantified using ImageJ software against a loading control β-actin. Data were presented as mean ± SEM, *p < 0.05, **p <0.01. Bar = 10 μm a–h
Sotthibundhu et al. Stem Cell Research & Therapy  (2016) 7:166 Page 8 of 16
autophagosomes with lysosome [31, 32]. We treated
iPSCs with 0, 5, 50, and 100 nM of bafilomycin A1 for
24 or 48 hours, with or without 200 nM rapamycin.
Bafilomycin A1 was shown to induce iPSC death in con-
centration/time-dependent manners. iPSC morphology
was significantly altered after 24 hours of bafilomycin
treatment at 50 nM (Fig. 5d, e) but not at 5 nM (Fig. 5b).
At 100 nM, bafilomycin markedly induced iPSC death in
24 hours, leading to grossly reduced cell density after
48 hours (Fig. 5e). Addition of 200 nM rapamycin
significantly attenuated bafilomycin-induced cell death,
improved iPSC survival, and increased iPSC cell density
at 48 hours of bafilomycin treatment (Fig. 5g).
Western blotting showed that bafilomycin enhanced
both LC3B-I and LC3B-II bands by blocking basal
autophagic flux. Rapamycin induced LC3B expression
and caused a shift from LC3B-I to LC3B-II (Fig. 5h, i).
Treatment of iPSCs with both rapamycin and bafilomycin
A1 increased conversion of LC3B-II from LC3B-I similar
to rapamycin treatment alone, thereby attenuating bafilo-
mycin-induced cell death (Fig. 5c, d). These data further
strengthen the importance of autophagy in iPSCs, because
blockage of fusion of autophagosomes with lysosome rap-
idly induces iPSC death. Meanwhile, addition of rapamy-
cin significantly improves iPSC survival.
Prolonged treatment with rapamycin induces formation
of uniform aggregates
We next cultured iPSCs in Geltrex-coated dishes in the
presence of 200 nM of rapamycin and examined the
long-term effects on the maintenance of iPSCs. We first
noticed the following morphological changes: the per-
ipheral cells of the iPSC colonies first started to elongate
(Fig. 6d) after 3 days, and cells at the edge produced an
unknown matrix which formed a firm line at the border
of the colony after 6 days to limit iPSC colony expansion
sideway (Fig. 6f, g); rapamycin altered iPSC cell junctions,
and cell borders became more obvious after 2 days of
Fig. 5 Rapamycin attenuates bafilomycin A1-induced iPSC death. iPSCs were treated with 0 (a), 5 nM (b), 50 nM (c), and 100 nM (d, e) of bafilomycin
for 24 hours (a–d) or 48 hours (e). Bafilomycin A1 induced cell death in a concentration-dependent manner (a–d), leading to substantial cell loss after
48 hours at 100 nM (d). Addition of 200 nM rapamycin attenuated bafilomycin A1-induced cell death and maintained iPSC normal cell density (f, g).
(h) Anti-ACTIN and Anti-LC3B immunoblotting were carried out with iPSC lysates from control iPSCs (Con), or 24 hours of treatment with 200 nm of
rapamycin (Rap), or with 100 nM of bafilomycin A1 (Baf), or with both (Rap + Baf). (i) Relative abundance of the LC3B-II/I ratios was quantified against a
loading control β-actin. Data were presented as mean ± SEM, *p < 0.05, **p <0.01, n = 4. Bar = 50 μm a, b
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treatment (Fig. 6c, d); and iPSCs continued to prolif-
erate in the central areas of colonies, together with
the limitation to expand sideways and reduce cell–cell
contacts, and round EB-like spheres were formed and
detached from the culture dish before and after 6 days
of rapamycin treatment (Fig. 6e, f ).
The average aggregate size at 6 days was 64,793 ±
18,779 μm2 (n = 13). The round spheres continued to
detach and grow after 9 days of treatment, and
reached sizes of 112,251 ± 17,422 (002 V, n = 8),
104,640 ± 27,265 (JOM, n = 13), and 105,381 ±
13,468 μm2 (LV1, n = 7) in three independent iPSC
lines, respectively. However, the control EBs resulting
from the cut-and-paste method varied significantly in
shape and size (Fig. 7f–h). These were 52,328 ± 25,518
(002 V, n = 10), 80,518 ± 77,708 (JOM, n = 20), and 75,652
± 51,944 μm2 (LV1, n = 22), respectively, and displayed
consistently large variation (SD) in sizes within each line
(Fig. 7b). These data show that high concentrations of
rapamycin treatment can induce iPSC detachment and
spontaneous formation of uniformly sized aggregates.
Rapamycin treatment accelerates differentiation of
human iPSCs
To determine the nature of the floating spheres resulting
from rapamycin treatment, we extracted proteins from the
aggregates and compared them with EBs generated via the
cut-and-paste method by immunoblotting with three
germ layer markers of α-fetoprotein (AFP for endoderm),
α-smooth muscle actin (ASM for mesoderm), and βIII
tubulin (TUJ1 for ectoderm), together with autophagy
marker LC3B-II (Fig. 8a). The expression of these marker
proteins was 2–3-fold higher in the rapamycin-induced
spheres (Fig. 8a–c).
To examine the differentiation potential of aggre-
gates, we plated them for spontaneous differentiation
and comparison with EBs made mechanically. Cells
with neuronal morphology appeared after 3 days
without neuronal induction (Fig. 8j–l), and many were
stained positive for neural stem cell marker NESTIN
(Fig. 8m). After 5 days of spontaneous differentiation, we
carried out immunocytochemical staining with AFP, ASM,
and TUJ1 and obtained significantly higher proportions of
cells positive for these makers in cells derived from
rapamycin-induced spheres (Fig. 8g–i), compared with
cells differentiated from the conventional EBs (Fig. d–f ).
To illustrate mechanism(s) of rapamycin-induced iPSC
differentiation, we investigated NANOG expression after
4 days of treatment by immunoblotting (Fig. 8l). Rapamy-
cin was shown to downregulate NANOG expression in a
concentration-dependent manner, and significant reduc-
tions were detected at 100 nM (p < 0.05), 200 nM (p <
0.01), or 300 nM of rapamycin treatment (p < 0.01,
Fig. 8m). These data suggest that rapamycin-induced
spheres are similar to conventional EBs in pluripo-
tency of differentiation, they are non-biased in differ-
entiating into three lineages, but differentiate in an
accelerated pace, in association with downregulated
NANOG expression during EB formation.
Fig. 6 Time course of rapamycin-induced cell detachment and EB formation. iPSCs were cultured in the presence of 200 nM rapamycin. Bright-field
microscopic images were taken as untreated control (a) and after 1 day (b), 2 days (c), 3 days (d) and 6 days (e, f) of treatment. EB-like spheres were
spontaneously formed after 6 days of rapamycin treatment. (c, e, f) The border of the iPSC colonies formed a line after day 6 to limit colony expansion
sideways (arrowheads). (e) Areas of iPSC detachment were filled with a thin layer of iPSCs (*). (f) Four EB-like spheres of comparable size were captured
in the fields (arrowheads). (g) Magnified view (4×) of the border area with arrowheads in f. Bar = 100 μm a–d; 200 μm e, f
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Rapamycin regulates adherens junctions and actin
cytoskeleton in human iPSCs
To identify potential molecular mechanisms associated
with rapamycin-induced iPSC detachment, we performed
quantitative mass spectrometry analysis with protein
extracts from control iPSCs and iPSCs treated with 50 or
100 nM of rapamycin for 3, 6, and 9 days respectively
(n = 3 for each). A total of 6145 proteins were quanti-
tatively identified, and 220 proteins were identified by
statistical analyses, which were systematically altered
at different time points and at both rapamycin con-
centrations (one-way ANOVA, two-tailed, p < 0.05).
Gene ontology (GO) analyses of the 220 targets with
the STRING database revealed that adherens junc-
tions (17 hits, p = 6.49 × 10–6) and actin cytoskeleton
(9 hits, p = 0.022) were significantly enriched in the
rapamycin-treated cells (Fig. 9), which integrated into
an interactive network (Fig. 9f ).
Of the 17 adherens junction molecules, nine
(ACTN4, BSG, EPHA2, EZR, FLNB, PDLIM1, PPIA,
SHROOM3, RPLP0) were downregulated and eight
(ABI2, GSN, ACTR3, ARF6, RALA, RPL7A, RPL19,
RPL27) were upregulated (Fig. 9a–c). Of the nine actin
cytoskeleton-associated proteins, six (ACTN4, CGN, EZR,
FGD4, SERPINA3, TTN) were downregulated and
three (CTTNBP2NL, GSN, SEPT11) were upregulated
(Fig. 9d, e). Consistent with the morphological changes,
these data suggest that alterations of adherens junctions
and cytoskeleton are the key pathways in rapamycin-
induced iPSC behavior.
Discussion
Autophagy is a cellular mechanism to maintain minimal
cell activity for viability in response to nutrient limitations
and cell stress, by degrading and recycling cytoplasmic
proteins and subcellular organelles via the fusion of a
double-membrane-bound vesicle, autophagosome, and
lysosome [17, 33]. Autophagy plays an essential role in
cellular reprogramming and the basal level of autophagy
increases in aging human skin fibroblasts, which may
affect different reprogramming efficiency [34]. There
appears no correlation with sex (all male) or age (4–20
years) in the fibroblast lines we have used, but there is
correlation with heath status, which requires validation in
larger sample sets. In this study we demonstrate abundant
presence of large autophagic vacuoles in early fibroblast
reprogramming and smaller ones during iPSC mainten-
ance. We show a high basal level of key components of
autophagy in 12 iPSC lines derived from 10 independent
donors, and prolonged rapamycin treatment resulted
spontaneous formation of uniformed sized EBs with accel-
erated differentiation pace.
Fig. 7 Rapamycin induces spontaneous formation of uniform sizes of EBs. (a–c) Images of floating spheres appeared after 9 days of rapamycin
treatment (200 nM) from three iPSC lines. (d–f) Images of EBs made after 9 days from the cut-and-paste method. (g) EB area sizes (μm2) were
quantified with ImageJ software and data were presented as mean ± SD. The X-axis in panel (g): 6f, 7a/b, 7c, 7d, 7e, 7f represents figure number, from
which the EB sizes were quantified. Note the round shape and uniform sizes of EBs from rapamycin treatment (a–c), in contrast to irregular shape and
sizes of EBs resulted from the same iPSC lines by mechanical method (d–f). Bar = 200 μm. EB embryoid body
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In previous studies, lack of autophagy components of
Atg3, Atg5, or Atg7 was shown to render MEF cells
defective in iPSC colony formation [15], and lack of two
different autophagy genes, atg5 and beclin1, displayed a
defect in EB formation during development [35]. The
reprogramming was entirely blocked also in Tsc2–/– som-
atic cells with hyperactivated mTOR activity which
suppressed autophagy [14]. Subtle tuning of the mTOR
activity with inhibitors (i.e., 0.3–1 nM rapamycin or 0.1
nM PP242) was found to increase reprogramming
efficiency [18]. Mechanistically, the reprogramming factor
Sox2 could bind to mTOR promoter and repress mTOR
expression and activate autophagy [15]. These data
together showed that reduced mTOR activity and elevated
autophagy were required during cellular reprogramming,
which is consistent with our observation that abundant
large autophagic vacuoles are present in early fibroblast
reprogramming, which become smaller during the subse-
quent passaging.
Balanced autophagy and mTOR activity is also essential
for the maintenance and differentiation of pluripotent
stem cells. Human ES cells were shown previously to have
a tight regulation of the mTOR signaling to mediate
protein translation for maintaining the pluripotent status
[36]. Activation of p70S6K, a mTOR downstream factor,
was shown to induce differentiation of human ES cells
Fig. 8 Rapamycin treatment accelerates differentiation of human iPSCs in association with decreased NANOG expression. a Proteins were extracted from
rapamycin-induced spheres and control EBs, and blotted with antibodies against LC3B, AFP, ASM, TUJ1, and β-actin. 1, 2, 3 in panel (a) indicate source of
proteins from three independent iPSC lines. b Relative protein expression was quantified against β-actin and (c) compared between two methods,
presented as mean ± SEM. Note a 2–3-fold increase of LC3B, AFP, ASM, and TUJ1 expression in rapamycin-induced spheres. Rapamycin-induced
spheres and control EBs were plated for spontaneous differentiation for 3 days (j, k) or 5 days (d–i), and stained for NESTIN (k), TUJ1 (d, g), ASM (e, h),
or AFP (f, i). Note the presence of more immune-positive cells in derivatives of rapamycin-induced spheres (g–i) compared with cells differentiated from
conventional EBs (d, f). (l) Proteins were extracted from iPSCs treated with rapamycin at 0, 1, 10, 100, 200, or 300 nM for 4 days, and immunoblotted
with anti-NANOG, showing concentration-dependent reduction of NANOG expression after rapamycin treatment. m Relative abundance of NANOG
expression after 4 days of rapamycin treatment. Bar = 100 μm d–i; 50 μm j, k. *p < 0.05, **p < 0.01. Con control, EB embryoid body
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[36], whereas inhibition of mTOR autophosphorylation by
20 nM rapamycin was reported to disrupt p70S6K-
mediated translation, but not to alter cell viability or ex-
pression of the pluripotency markers [37]. In contrast, the
mTOR was necessary for growth and proliferation of early
mouse embryos and ES cells, and disruption of the mouse
mTOR gene prohibited ES cell development [38, 39].
Interestingly, 100 nM rapamycin was previously shown to
reduce the size and rate of EB formation in human amni-
otic fluid stem cells [40]. In contrast, our study demon-
strated that a high concentration of rapamycin induced
EB formation in iPSCs. Inhibition of the mTOR activity
with high concentrations of rapamycin also greatly im-
paired somatic cell reprogramming [14], and 100 nM
rapamycin was used to primer hepatocyte differentiation
of iPSCs prior to Activin A induction [41]. This is consist-
ent with our data that rapamycin downregulates NANOG
expression in a concentration-dependent manner and ac-
celerates iPSC differentiation.
To uncover rapamycin pathways in iPSCs, we carried
out quantitative mass spectrometry. The STRING Gene
Ontology analyses revealed that actin cytoskeleton and
adherens junctions were the integrated pathways regulated
by rapamycin. For example, ACTN4, BSG, CGN, EPHA2,
EZR, FGD4, FLNB, PDLIM1, PPIA, SHROOM3, RPLP0,
SERPINA3, and TTN were significantly downregulated,
whereas ABI2, CTTNBP2NL, GSN, ACTR3, ARF6, RALA,
RPL7A, RPL19, RPL27, and SEPT11 were upregulated.
Fig. 9 Rapamycin regulates adherens junctions and actin cytoskeleton pathways in iPSCs. Three independent lines of iPSCs were maintained in mTeSR™
(con) or in the presence of 50 or 100 nm rapamycin for 3, 6, or 9 days. Proteins were harvested for mass spectrometry analyses. (a–e) Time-course changes
of protein expression (mean ± SEM, n= 3). *p< 0.05. (f) Molecular network for selected proteins whose expression was altered. Data show the network of
interactions between adherens junctions and actin signaling by the STRING database. Arrows indicate upregulation or downregulation of the protein
expression after rapamycin treatment. Each * represents p < 0.05 for the respective culture condition in comparison to the control iPSCs in black bar
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Actin is critical for cell shape, adhesion, and migration.
The dynamics of actin cytoskeleton are modulated by
rapamycin targets of SHROOM3, EZR, and GSN. For ex-
ample, SHROOM3 is required for the apical localization
of F-actin/myosin II [42]. EZR links the plasma membrane
to actin and is involved in adhesion and migration. Inhib-
ition of EZR expression reduced adhesiveness in colorectal
cancer cells [43]. GSN knockdown decreased cell viability
and tumor cell invasion, whereas GSN overexpression
correlates with proliferative and invasive capacities [44].
BSG promotes cell–cell adhesion, and its downregulation
altered the actin/Spectrin network [45]. Reduced expres-
sion of SHROOM3, EZR, and BSG in the rapamycin-
treated iPSCs is therefore in line with reduced cell
adhesion in the literature.
ACTN4, FLNB, and PDLIM1 are actin-binding proteins.
ACTN4 is concentrated at sharp extension and at the edge
of cell clusters [46], and FLNB regulates direct communica-
tion between the cell membrane and the cytoskeletal
network [47]. PDLIM1 functions as an adapter to recruit
other LIM-interacting proteins to the cytoskeleton, and
suppression of PDLIM1 resulted in cell spreading and the
loss of stress fibers and focal adhesions [48]. In addition,
ACTR3 is also essential to cell shape and motility, and is an
ATP-binding component of the ARP2/3 complex, which
regulates actin polymerization. The complex can be acti-
vated by ABI, and knockdown of ABI markedly inhibits
cell–cell junctions [49]. Rapamycin-induced changes in the
expression of ACTN4, ACTR3, FLNB, and PDLIM1 are
therefore also likely to affect actin cytoskeleton.
Some of the rapamycin targets are GTPase activity
related, such as downregulated EPHA2 and upregulated
ARF6 and RALA. GTPases are involved in cell adhesion
migration and oncogenic transformation. For example,
EphA2 is transmembrane receptor tyrosine kinase activat-
ing and prompts cells to round up and detach from their
neighbors [50]. RALA is a small GTPase, and constitu-
tively active RALA promotes anchorage-independent
growth signaling [51]. ARF6 is a small GTPase to balance
with RAB35 GTPase by cells during cell migration and ad-
hesion. Increased ARF6 activity from RAB35 knockdown
enhances cadherins accumulation and reduces cell–cell
adhesion. The loss of RAB35, however, correlates with en-
hanced cell migration [52]. Reduced EPHA2 and increased
ARF6 and RALA expression may therefore also contribute
to rapamycin-induced iPSC detachment. Together these
data showed that rapamycin regulates an array of
adherens junctions and actin-modifying molecules, which
collectively alter iPSC adhesion.
Conclusions
In this study, we demonstrate that autophagy is a prom-
inent feature of reprogramming cells and stable iPSCs.
The basal level of autophagy is universally present among
human iPSC lines, which is significantly higher than par-
ental fibroblasts. Block of autophagy by bafilomycin in-
duces iPSC death. Rapamycin activates autophagy in
concentration-dependent and time-dependent manners
and attenuate bafilomycin toxicity in iPSCs. Prolonged
rapamycin treatment induces cell detachment and forma-
tion of uniformly sized EBs from human iPSCs, with
altered expression of adherens junctions and actin-
modifying molecules. Rapamycin downregulates NANOG
expression, induces EB formation, and accelerates cell
differentiation into three germ-layer lineages. These find-
ings are significant in two ways. Firstly, the 3D micro-
environment including shape and size of EBs can affect
differentiation. The iPSCs are supersensitive to enzyme
dissociation and therefore the “hanging drop” technique is
difficult to apply, despite being available to generate uni-
form EBs from ES cells over 20 years ago. Rapamycin may
therefore assist generation of uniformly sized EBs with
round shape, which may reduce the heterogeneity of the
end cell types. Secondly, differentiation of mature and
functional cell types from human iPSCs is time consum-
ing, and the accelerated differentiation associated with
rapamycin treatment is promising in shortening the differ-
entiation duration. Rapamycin may therefore help over-
coming the challenges associated with phenotypic
characterization, drug discovery, and cell replacement
therapy for neurological disorders.
Additional file
Additional file 1: Figure S1. Showing that rapamycin induces LC3B
expression in human fibroblasts. Three lines of human fibroblasts (F1, F2, F3)
were treated without (–) or with (+) 100 nM rapamycin overnight. The
protein lysates were run of 15 % SDS-PAGE and blotted with anti-LC3B and
anti-GAPDH. Two bands of LC3B-I (16 kDa) and LC3B-II (14 kDa) were seen.
Rapamycin is shown to induce LC3B-I expression after 24 hours of treatment.
(TIF 172 kb)
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